Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
about
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis opticaAutoinjector preference among patients with multiple sclerosis: results from a national survey.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.
P2860
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacokinetics and safety of ...... chronic lymphocytic leukaemia.
@ast
Pharmacokinetics and safety of ...... chronic lymphocytic leukaemia.
@en
type
label
Pharmacokinetics and safety of ...... chronic lymphocytic leukaemia.
@ast
Pharmacokinetics and safety of ...... chronic lymphocytic leukaemia.
@en
prefLabel
Pharmacokinetics and safety of ...... chronic lymphocytic leukaemia.
@ast
Pharmacokinetics and safety of ...... chronic lymphocytic leukaemia.
@en
P2093
P2860
P356
P1476
Pharmacokinetics and safety of ...... chronic lymphocytic leukaemia.
@en
P2093
Alain Delmer
Christine McIntyre
Florence Hourcade-Potelleret
Michael Brewster
Olivier Catalani
Pakeeza Sayyed
Sarit Assouline
Valeria Buccheri
Xavier Badoux
P2860
P304
P356
10.1111/BCP.12662
P407
P577
2015-04-19T00:00:00Z